(Q36456488)

14 August 2017

1 reference

title

Mechanisms leading to the development of hormone-resistant prostate cancer (English)

1 reference

14 August 2017

1 reference

Susan Kasper

1

1 reference

PubMed ID

16631458

14 August 2017

Michael S Cookson

series ordinal

2

1 reference

14 August 2017

1 May 2006

1 reference

Urologic Clinics of North America

14 August 2017

1 reference

14 August 2017

33

1 reference

14 August 2017

2

1 reference

14 August 2017

201-10, vii

1 reference

Androgen deprivation therapy for prostate cancer

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Epidemiology of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Treating the biochemical recurrence of prostate cancer after definitive primary therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Mechanisms of androgen-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

The current role of chemotherapy in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

The development of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Molecular determinants of resistance to antiandrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Mutation of the androgen receptor causes oncogenic transformation of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

The androgen receptor gene mutations database (ARDB): 2004 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Expression and function of androgen receptor coactivators in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Androgen receptor in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Androgen receptor corepressors: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Stem cells, cancer, and cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Neurogenic origin of human prostate endocrine cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Role of p63 and basal cells in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Cell differentiation lineage in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Identification of intermediate cell types by keratin expression in the developing human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Epithelial-mesenchymal transitions in tumour progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Desmosomes: differentiation, development, dynamics and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

E-cadherin-catenin cell-cell adhesion complex and human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

A causal role for E-cadherin in the transition from adenoma to carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

Etiology and disease process of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UCL.2005.12.010

1 reference

14 August 2017

1 reference

PubMed ID

16631458